Adjuvant Chemotherapy Options in HER2-Positive Breast Cancer

Video

This video examines chemotherapy options for HER2-positive breast cancer in the adjuvant setting, and what evidence there is for alternatives to an anthracycline backbone.

In this video, Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, discusses chemotherapy options for HER2-positive breast cancer in the adjuvant setting.

Most pivotal adjuvant studies have used anthracyclines as a backbone, but this form of chemotherapy is associated with higher cardiac toxicity, among others.

Here Tolaney examines one study that used an alternative regimen (docetaxel, carboplatin, and trastuzumab, or TCH) and looks ahead at the potential for new biologic agents to change the treatment approach in these patients.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
2 experts in this video